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Abstract 
T u m o r   s u p p r e s s o r s   r e f e r   t o   a   l a r g e   g r o u p   o f   m o l e c u l e s   t h a t   a r e   c a p a b l e   o f   c o n t r o l l i n g   c e l l  
division, promoting apoptosis, and suppressing metastasis. The loss of function for a tumor 
s u p p r e s s o r   m a y   l e a d   t o   c a n c e r   d u e   t o   u n c o n trolled cell division. Because of their importance, 
extensive studies have been undertaken to understand the different functional mechanisms of 
tumor suppressors. Here, we briefly review the four major mechanisms, inhibition of cell 
division,  induction  of  apoptosis,  DNA  damage  repair,  and  inhibition  of  metastasis.  It  is 
noteworthy that some tumor suppressors, such as p53, may adopt more than one mechanism 
for their functions.  
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Introduction 
Cancer  cells  are  basically  transformed  from 
normal cells (1). The transformation usually requires 
genetic mutations in proto-oncogenes and/or tumor 
s u p p r e s s o r s   ( 1 ) .   T h e s e   m u t a t i o n s   c a n   b e   d i r e c t l y   i n-
duced by specific cancer-c a u s i n g   a g e n t s   s u c h   a s   r a d i-
a t i o n s ,   c h e m i c a l s ,   h o r m o n e s ,   v i r u s e s   a n d   g e n etic fac-
t o r s   ( 2 ) .   A f t e r   t r a n s f o r m a t i o n ,   t h e   c a n c e r   c e l l s   l o s e  
their ability to control cell division, but still maintain 
certain characteristics of the cells from which they are 
derived. Tumor suppressors prevent cancer by relia-
bly controlling cell division, promoting apoptosis, and 
suppressing metastasis (3). Once a tumor suppressor 
b e c o m e s   i n a c t i v e ,   c e l l   d i v i s i o n   m a y   p r o c e e d   o u t   o f  
c o n t r o l   a n d   t h i s   m a y   l e a d   t o   c a n c e r .   T u m o r   s u p p r e s-
s o r s   a f f e c t   b o t h   t h e   i n i t i a t i o n   a n d   t h e   d e v e l o p m e n t   o f  
cancer,  and  generally   f o l l o w   t h e   c l a s s i c   “ t w o -hit” 
model (3-5). They are encoded by two alleles because 
c h r o m o s o m e s   a r e   p a i r e d   i n   h u m a n s   ( 3 ) .   I f   o n e   a l l e l e  
becomes mutated (heterozygosis) or underexpressed, 
the other can still express the appropriate tumor sup-
pressor to inhibit cell division (5).  When both alleles 
a r e   m u t a t e d   o r   u n d e r e x p r e s s e d ,   t h e   i n h i b i t i o n   o f   c e l l  
division is reduced and even lost (5). However, there 
are  also  exceptions,  such  as  tumor  suppressor  p27.  
T h e   p r o d u c t i o n   o f   p 2 7   f r o m   t h e   u n m u t a t e d   a l l e l e   i s  
not s u f f i c i e n t   e n o u g h   t o   b r i n g   t h e   c e l l   t o   i t s   o r i g i n a l  
condition in the heterozygote, and the cell mitosis can 
only be arrested when both alleles are unmutated (6). 
Mechanisms of Tumor Suppression 
M a n y   t u m o r   s u p p r e s s o r s   h a v e   a c t i v i t y   i n   b o t h  
normal and tumor cells; whereas the others, such as 
p 5 3 ,   a r e   i n a c t i v e   i n   n o r m a l   c e l l s   a n d   o n l y   a c t i v a t e d   b y  
p o t e n t i a l   c a n c e r   r i s k s .   A   t u m o r   s u p p r e s s o r   m a y   p o s-
sess  multiple  mechanisms  to  suppress  cancer  cell 
g r o w t h   ( 3 ) .   F o r   e x a m p l e ,   t h e   m o s t   i m p o r t a n t   t u m o r  
suppressor p53, w h i c h   i s   a s s o c i a t e d   w i t h   a b o u t   5 0 %   o f  
h u m a n   c a n c e r   c a s e s   ( 7 ) ,   c a n   t r i g g e r   D N A   r e p a i r  
processes,  induce  the  transcription  of  other  tumor 
suppressors, such as p21 and p16, and initiate cell 
a p o p t o s i s   ( 3 ,   8 ,   9 ) .   D e s p i t e   t h e   t r e m e n d o u s   g r o w t h   i n  




suppressors  (10),  the  exact  underlying  mechanisms 
through which the tumor suppressors function are not 
always clearly revealed. To date, four major mechan-
isms have been revealed for tumor suppressors: sup-
pression of cell division, induction of apoptosis, DNA 
damage repair and inhibition of metastasis. 
Suppression of Cell Division 
Suppression of cell division is the main mechan-
i s m   f o r   m o s t   t u m o r   s u p p r e s s o r s .   T h e   t u m o r   s u p p r e s-
sors that adopt this mechanism include retinoblasto-
ma protein (Rb), adenomatosis polyposis coli (APC), 
alternate reading frame (ARF), RIZ1, p15, p16, p18, 
p19, p21, p27, and p53 (8, 9, 11-2 1 ) .   R b ,   w h i c h   i s   t h e  
first  discovered  tumor  suppressor,  inhibits  the  tran-
s c r i p t i o n   o f   s p e c i f i c   g e n e s   r e q u i r e d   f o r  mitosis 
through binding to transcription factors such as E2Fs, 
which  are  key  cell  proliferation  regulators  (12,  13). 
T u m o r   s u p p r e s s o r   p 5 3 ,   w h i c h   c a n   a l s o   b i n d   t o   D N A ,  
stimulates  the  expression  of  other  genes,  such  as 
WAF1/CIP1 encoding p21 (8, 22). APC stabilizes mi-
crotubules to inhibit mitosis (15) and interferes with 
cell adhesion to its growing matrix (23). The interfe-
rence with cell adhesion results in indirect suppres-
sion of cell division due to contact inhibition. It has 
been observed that a few tumor suppressors may act 
in cooperation to inhibit cell mitosis (3). Tumor sup-
p r e s s o r s   p 1 5 ,   p 1 6 ,   p 1 8 ,   p 1 9 ,   p 2 1   a n d   p 2 7   i n h i b i t   c y c-
lin-dependent kinases (CDKs), which, in turn, inhibit 
Rb (11, 24). When CDKs are inhibited, Rb is kept ac-
tive to suppress cell di v i s i o n   ( 2 4 ) .   A R F   i s   c a p a b l e   o f  
r e l o c a t i n g   t h e   m u r i n e   d o u b l e   m i n u t e   ( M D M 2 ) ,   a   c r i t-
ical negative regulator of p53 inhibitor, into nuclei to 
activate cellular p53 (25). In addition, epigenetic reg-
ulation may play a role in tumor suppressing actions. 
Histone  methyltransferases are recently deemed as a 
special  group  of  tumor  suppressors,  which  can  di-
rectly inhibit mitosis via changing the conformation of 
histone to block double-strand DNA unwinding (26). 
Induction of Apoptosis 
Apoptosis, or programmed cell death, is another 
f u n c t i o n a l   m e c h a n i s m   o f   t u m o r   s u p p r e s s i o n .     E x a m-
p l e s   o f   t h i s   g r o u p   o f   t u m o r   s u p p r e s s o r s   a r e   p 5 3 ,   A P C ,  
cluster of differentiation 95 (CD95), bridging integra-
tor  1  (Bin1)  and  phosphatase  and  tensin  homolog 
(PTEN) (27-31). Unlike premature cell death, apopto-
sis  maintains  normal  homeostasis  and  suppresses 
c a n c e r   ( 3 2 ,   3 3 ) .   I t   i s   r e g u l a t e d   b y   m a n y   d i f f e r e n t  
pathways integrating both positive and negative reg-
ulations  (34).  p53  mediates  apoptosis  through  two 
major  pathways,  the  extrinsic  pathway,  which  acti-
vates a caspase cascade including caspase-9, -3, -6 and 
-7,  and  the  intrinsic  pathway,  which  promotes  the 
apoptosome  formation  via  the  Bcl-2  family  (28,  35).  
APC, which has been observed to be frequently mu-
tated  in  colorectal  cancer,  promotes  transcrip-
tion-independent  apoptosis  via  caspase  8  (27).  The 
APC-mediated  apoptosis  can  be  abolished  by  cas-
pase-8 inhibitor Z-IETD-F M K   ( 2 7 ) .   C D 9 5   i s   o v e r e x-
pressed in cancer cells and acts as an important re-
c e p t o r   f o r   c e l l   d e a t h   ( 2 9 ,   3 6 ) .   U p o n   b e i n g   r e c o g n i z e d  
immunogenically by a specific ligand expressed in the 
cytotoxic T killer cells, CD95 initiates apoptosis in the 
c a n c e r   c e l l s   ( 3 7 ) .   B i n 1 ,   w h i c h   i s   a   c e l l   d e a t h   a g e n t ,  
mediates apoptosis to suppress cancer by c-Myc (30). 
I n   c o n t r a r y   t o   t h e   a b o v e   d i s c u s s e d   t u m o r  suppressors 
that directly induce apoptosis, PTEN utilizes an al-
ternative mechanism to promote apoptosis. It inacti-
vates phosphatidylinositol 3,4,5-triphosphate  (PIP3), 
which  is  important  for  anti-apoptosis  and  aids  in 
cancer cell survival (31). Although some tumor sup-
pressors can both inhibit mitosis and induce apopto-
s i s ,   a p o p t o s i s   i s   n o t   n e c e s s a r i l y   i n d u c e d   b y   t h e   i n h i b i-
tion of mitosis (38). 
DNA Damage Repair 
T h e   t u m o r   s u p p r e s s o r s   t h a t   c a n   h e l p   i n   D N A  
d a m a g e   r e p a i r   i n c l u d e   m u t S   h o m o l o g   2   ( M S H 2 ) ,  
mutL  homolog  1  (MLH1),  Ataxia-telangiectasia- 
mutated  gene  product  (ATM),  breast  cancer  protein 
(BRCA),  Nijmegen  breakage  syndrome  1  (NBS1), 
Fanconi-Anemia−related tumor suppressor (FA), and 
p53 (3, 39-4 3 ) .   T h e y   a r e   a b l e   t o   f i x   D N A   d a m a g e s ,  
including  mismatch  and   v a s t   d a m a g e   t o   o n e   o f   t h e  
D N A   d o u b l e   s t r a n d s .   G e n e r a l l y ,   p 5 3   c a n   i n d u c e   n u c-
leotide excision repair to remove damaged DNA por-
tions  and  mediate  synthesis  from  the  other  strand; 
whereas MSH2 and MLH1 can repair DNA mismatch 
(3, 39, 40). ATM is a general sensor to DNA damage 
and phosphorylates p53, BRCP, NBS1 and FA to ac-
t i v a t e   t h e   D N A   r e p a i r   p r o c e s s   ( 3 ,   4 1 ) .   B R C A   a n d   p 5 3  
w o r k   t o g e t h e r   i n   n u c l e o t i d e   e x c i s i o n   r e p a i r   o f   D N A  
a d d u c t s   ( 4 2 ) .   N B S 1   a n d   F A   m a k e   D N A   r e s i s t a n t   t o  
crosslinking,  and  may  amplify  the  phosphorylation 
signal  from  ATM  (43).  In  addition,  thymine-DNA 
g l y c o s y l a s e   ( T D G )   i s   p r o p o s e d   a s   a   t u m o r   s u p p r e s s o r  
candidate (44-4 6 ) .   P r e v i o u s   s t u d i e s   h a v e   s h o w n   t h a t  
5-methylation of cytosine could lead to spontaneous 
hydrolytic deamination to produce the C→T transi-
tion  mutation  and  T-G mismatches (44-4 6 ) .   T D G   r e-
cognizes the T-G mismatch, removes the mismatched 
T   t h r o u g h   h y d r o l y s i s   o f   i t s   N -glycosidic  bond,  and 
initiates  a  nucleotide  excision  repair  (44-4 6 ) .     T h e  
C→T transition mutation happens frequently in hu-
man tumors and counts for about 24% of p53 muta-
tions  (44,  47-5 0 ) .   R e c e n t l y ,   T D G   w a s   s h o w n   t o   b e   a  




Inhibition of Metastasis 
T h e   m a j o r i t y   o f   c a n c e r   d e a t h   i s   c a u s e d   b y   m e-
tastasis (52). During metastasis, tumor cells have sig-
nal interactions with endothelial cells to initiate an-
g i o g e n e s i s   a n d   b r e a k   d o w n   v a s c u l a r   w a l l s .     T h e s e  
actions promote their spread. Tumor suppressors that 
can inhibit metastasis consist of metastin, breast can-
cer metastasis suppressor 1 (BRMS1), tissue inhibitor 
of  metalloproteinase  (TIMP),  cofactor  required  for 
specificity  protein  1  activation  (CRSP),  and 
KAL1/CD82  (53-64). The binding of metastin to the 
metastin receptor (orphan G protein-coupled receptor 
GPR54) increases the expression and activity of focal 
adhesion kinase (FAK) and inhibits the metastasis of 
m e l a n o m a   c e l l s   ( 5 3 ) .   I t   h a s   a l s o   b e e n   s h o w n   t h a t   m e-
t a s t i n   t r i g g e r s   p h o s p h o l i p a s e   C   a c t i v a t i o n ,   a r a c h i-
donic acid release and extracellular signal-regulated 
kinase  (ERK)  phosphorylation  in  Chinese  hamster 
ovary (CHO) cells overexpressing metastin receptor 
(54, 55). BRMS1 regulates gene transcription through 
interaction  with  the  mSin3  histone  deacetylase 
( H D A C )   c o m p l e x   ( 5 7 ) .   T I M P s   c a n   b i n d   n o t   o n l y   a l l  
matrix  metalloproteinases  (MMPs)  in  their  active 
forms  but  also  MMP-2  and  MMP-9   i n   t h e i r   l a t e n t  
forms. TIMPs reduce cancer metastasis by inhibiting 
the  cancer  cell-released MMPs, maintaining the inte-
grity  of  extracellular  matrices,  and  preventing  the 
penetration  of  cancer  cells  through  the  base  mem-
b r a n e   o f   b l o o d   v e s sels (58-6 0 ) .   C R S P   c a n   u p -regulate 
t h e   e x p r e s s i o n   o f   m e t a s t i n   ( 6 1 ) .   C D 8 2   i s   a   c e l l   s u r f a c e  
glycoprotein activated by p53 (62, 63). The expression 
levels of CD82 and p53 are strongly correlated (63). 
The exact mechanism for CD82 to inhibit cancer me-
tastasis is still unclear; however, it may inhibit cancer 
cell  migration/invasion  through  the 
FAK-Lyn-p130 CAS-CrkII pathway (64). 
Summary 
I n   s u m m a r y ,   w e   b r i e f l y   r e v i e w e d   t h e   f o u r   m a j o r  
functional mechanisms for human tumor suppressors. 
Some  tumor  suppressors,  such  as  p53,  may  utilize 
more than one mechanism for their suppressing func-
tions.  Recent  progress  in  structural  and  functional 
studies  of  tumor  suppressors  and  their  interactions 
with  other  molecules  has  benefited  the  design  and 
discovery  of  novel  anticancer  agents.  For  example, 
quite a few CDK inhibitors have been developed and 
some are already in clinical trials. 
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